RxDoctor Payments Data

Jeffrey Blackburn, MD

Cardiovascular Disease · Raleigh, NCNPI 1396928966

Payments from drug & device makers

$3,383in general payments, 2019–2025

Across 198 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$503
  • Johnson & Johnson$393
  • Sanofi-aventis U.S. LLC$318
  • Novartis$308
  • Pfizer$248
  • E.r. Squibb & Sons, L.L.C.$230
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,379100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,383 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$245,680
Medicare patients
1,014
Services billed
2,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban497$521,100
EntrestoSacubitril/Valsartan132$140,919
XareltoRivaroxaban109$130,750
MultaqDronedarone Hcl59$92,791
BrilintaTicagrelor98$68,738
JardianceEmpagliflozin66$63,590
Repatha SureclickEvolocumab37$34,478
FarxigaDapagliflozin Propanediol29$25,340
Propafenone Hcl ErPropafenone Hcl20$10,654
Metoprolol Succinate445$6,394
Dabigatran EtexilateDabigatran Etexilate Mesylate12$5,499
Atorvastatin Calcium265$3,151
Rosuvastatin Calcium155$2,610
Isosorbide Mononitrate ErIsosorbide Mononitrate117$1,972
Carvedilol256$1,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$521,100497 claims
NovartisEntresto$308$140,919132 claims
Johnson & JohnsonXarelto$393$130,750109 claims
AstraZenecaBrilinta, Farxiga$199$94,078127 claims
Sanofi-aventis U.S. LLCMultaq$318$92,79159 claims
Boehringer IngelheimJardiance$147$63,59066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →